Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3NETWORK 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Thoracic 2Plasma cell 2CNS 2Sarcoma 1

Conditions

Neuroblastoma 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Radiotherapy 58Temozolomide 37Vincristine 33Cyclophosphamide 31Etoposide 25Carboplatin 25Filgrastim 23Cisplatin 22Granulocyte Colony-Stimulating Factor 18Lomustine 14Doxorubicin 13Chemotherapy, Adjuvant 13Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Topotecan 11Radiation 11Isotretinoin 11Platinum 10sargramostim 9Specimen Handling 9Radiotherapy, Conformal 9Irinotecan 9Carmustine 91,2-diaminocyclohexaneplatinum II citrate 9etoposide phosphate 8Thiotepa 8Radiotherapy, Intensity-Modulated 8Radiosurgery 8Melphalan 8Immunohistochemistry 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Crizotinib × CNS × Clear all
NCT01606878 2024-01-05

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1 Completed
46 enrolled 24 charts
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1/2 Completed
122 enrolled 24 charts 2 FDA
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡